Polarean Imaging plc (AIM:POLX)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 965.63K -94.1% |
| Revenue (ttm) | 1.87M +37.3% |
| Net Income | -7.00M |
| EPS | -0.01 |
| Shares Out | 1.21B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,964,160 |
| Open | 0.0850 |
| Previous Close | 0.1000 |
| Day's Range | 0.0600 - 0.1250 |
| 52-Week Range | 0.0600 - 1.6000 |
| Beta | 0.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 24, 2025 |
About Polarean Imaging
Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States. The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. It also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; chest... [Read more]
Financial Performance
In 2024, Polarean Imaging's revenue was $3.09 million, an increase of 246.82% compared to the previous year's $890,933. Losses were -$8.54 million, -28.14% less than in 2023.
Financial numbers in USD Financial StatementsNews
Polarean Imaging expands Xenon MRI into cardiopulmonary drug development
Polarean announced the expansion of its Xenon MRI platform into cardiopulmonary pharma-sponsored drug development through a multi-center U.S. study in PH-ILD. Funded by a leading cardiopulmonary pharm...
Polarean Imaging’s XENOVIEW 3T coil passes Philips compatibility testing
Polarean Imaging (PLLWF) announces that its FDA-cleared XENOVIEW 3T Chest Coil has completed compatibility testing conducted by Philips and is now confirmed for use with Philips’ latest 3T MRI platfor...
Polarean Imaging signs exclusive distribution agreement with DK Healthcare
Polarean Imaging (PLLWF) signed an exclusive distribution agreement with DK Healthcare for the distribution of Polarean’s Xenon MRI platform in South Korea. This agreement represents Polarean’s second...
Polarean Imaging announces FDA expansion of XENOVIEW indication
Polarean Imaging (PLLWF) announces that the US Food and Drug Administration has approved the Company’s Supplemental New Drug Application to expand the indication of XENOVIEW. This approval immediately...
Polarean Imaging says Xenon MRI to be featured prominently at ATS 2025
Polarean Imaging (PLLWF) will be featured at the American Thoracic Society’s (ATS) 2025 Respiratory Innovation Summit, taking place May 16-17 at the Marriott Marquis in San Francisco, California. Pola...
Polarean Imaging, SimonMed collaborate to advance lung imaging
Polarean Imaging (PLLWF) announces a strategic collaboration with SimonMed Imaging to expand access to Polarean’s Xenon MRI platform. SimonMed Imaging operates in over 170 facilities across 11 states....
Polarean Imaging announces FDA clearance of XENOVIEW 3T chest coil
Polarean Imaging (PLLWF) has received 510(k) clearance from the U.S. Food and Drug Administration for the Company’s specialized MRI Chest Coil to now include GE HealthCare (GEHC) 3 Tesla MRI…
Polarean Imaging appoints Alan Huang as VP of sales
Polarean Imaging announced the appointment of Alan Huang, PhD as Vice President of Sales. Huang joins Polarean after nearly 12 years at Philips Healthcare, where he held various roles, most…
Polarean Imaging appoints Chase Hall as chief medical advisor
Polarean Imaging has appointed Chase Hall, M.D., as Chief Medical Advisor. Dr. Hall is an Associate Professor, Pulmonary, Critical Care and Sleep Medicine, at the University of Kansas Medical Center…
Polarean Imaging resumed with a Buy at Stifel
Stifel resumed coverage of Polarean Imaging with a Buy rating and 8 GBp price target. The company’s recent capital raise provides funding for the business until Q1 of 2026, the…
Polarean Raises $12.6 Million in Oversubscribed Financing Round to Accelerate XENOVIEW™ Commercialization and Strategic Growth Initiatives
DURHAM, NC and LONDON, June 20, 2024 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging...
Polarean Imaging partners with VIDA Diagnostics
Polarean has partnered with VIDA Diagnostics. The companies are partnering to develop solutions that further enable the Polarean xenon 129 MRI platform to accelerate clinical and research use. VIDA ha...
Polarean Imaging announces CMS has established new reimbursement code
Polarean announces that the Centers for Medicare & Medicaid Services, CMS, has established a new reimbursement code for the Polarean XENOVIEW technology, effective October 1, 2023. The code enables he...
Polarean Imaging receives FDA clearance for MRI chest coil
Polarean has received 510(k) clearance from the U.S. Food and Drug Administration for the Company’s specialized MRI chest coil to now include Philips 3.0T MRI scanners for the visualization of…
Polarean Imaging announces FDA approval of XENOVIEW
Polarean Imaging announces that the U.S. Food and Drug Administration has granted approval for its drug device combination product, XENOVIEW. XENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is…
FDA Approves Polarean's XENOVIEW™ (xenon Xe 129 hyperpolarized) for use with MRI for the Evaluation of Lung Ventilation
XENOVIEW represents the first and only hyperpolarized MRI contrast agent ● FDA approved indication includes both adolescents and adults representing a significant market opportunity XENOVIEW represent...